Meriofert Set

Follicle‑stimulating hormone (FSH) and luteinising hormone (LH), the active ingredient in Meriofert Set, is a gonadotropin presented as an injectable solution for intramuscular and subcutaneous use. It treats infertility related to anovulation and is used in assisted reproductive technologies in women. GNH USA supplies Meriofert Set as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Set is a gonadotropin used in fertility treatment pathways to stimulate ovarian function. - Anovulatory infertility: promotes follicular development and ovulation in women who do not ovulate spontaneously. - Controlled ovarian stimulation for assisted reproductive technologies: supports growth of multiple follicles for IVF cycles. - Ovulation induction in women undergoing IVF: enhances estradiol production and oocyte maturation to improve IVF outcomes.

Common Side Effects: - Injection site reactions: pain, redness, or swelling at the injection site. - Mild abdominal discomfort or pelvic pressure. - Nausea or mild headache. - Mild ovarian hyperstimulation syndrome (OHSS) presenting as bloating.

Serious or Rare Side Effects: - Severe OHSS: rapid weight gain, shortness of breath, or abdominal pain requiring medical attention. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Multiple pregnancy: increased risk of twins or higher-order gestations.

Precautions should be observed when using Meriofert Set to ensure patient safety. - Monitor ovarian response: perform ultrasound and estradiol measurements to adjust dosing. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Assess risk of ovarian hyperstimulation syndrome: use the lowest effective dose. - Use caution in patients with thromboembolic disorders: evaluate risk before treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions require careful management. Major Interactions (Avoid): - GnRH agonists: may amplify ovarian response leading to severe OHSS. - Oral contraceptives: can suppress endogenous gonadotropins, reducing efficacy. - Anticoagulants: increased risk of bleeding with ovarian cyst rupture.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: may affect ovarian response. - Insulin sensitizers (e.g., metformin): may alter follicular development. - Corticosteroids: may modify hormone metabolism and response.